Tag: hanmi pharmaceutical

hanmi pharmaceutical

Latest News

Korean obesity drug Eppe takes on Mounjaro, Wegovy with slimmer price tag

Hanmi Pharmaceutical plans to launch Korea’s first homegrown GLP-1 obesity treatment at wholesale prices well below Eli Lilly and Novo Nordisk's products.

2026.10.14

Price, potency and convenience: The hurdles facing Korea's future obesity drugs

The government has approved Korea's first domestically developed glucagon-like peptide-1 (GLP-1) obesity drug. But the Eppe Auto Injector will need a competitive price to shake up a market already dominated by Wegovy and Mounjaro.

2026.10.9

Most popular

Korea's first GLP-1 obesity drug wins approval with less weight loss but fewer side effects

Hanmi Pharmaceutical plans to launch its locally made weekly injection this month, aiming to compete on lower costs and stable supply.

2026.10.8

Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London on March 8, 2024. [REUTERS/YONHAP]

Korea pushes to tip weight loss drug market scale in their favor

Korean pharmaceutical firms are accelerating their push into the global obesity drug market as demand surges worldwide. This has sparked fierce competition among key players like HK inno.N, Ildong Pharmaceutical, Celltrion and Hanmi Pharmaceutical.

2026.2.6

Hanmi Pharmaceutical headquarters building in eastern Seoul [HANMI PHARMACEUTICAL]

Hanmi Pharma chief survives ousting attempt by late founder's son

Hanmi Pharmaceutical chief executive Park Jae-hyun retained his top post in the company, fending off an attempt by Lim Jong-yoon, the late founder’s son, to oust him as the family feud continues.

2024.9.2

Hanmi Pharmaceutical's headquarters in Songpa District, southern Seoul. [HANMI PHARMACEUTICAL]

Sanofi pulls out of Hanmi diabetes drug trials, ends contract

Paris-based Sanofi has decided to drop ongoing Phase 3 clinical trials and marketing rights of Hanmi Pharmaceutical’s efpeglenatide, a diabetes drug.

2020.9.9

Chairman of Hanmi Pharmaceutical Lim Sung-ki dead at 80

Lim Sung-ki, founder and chairman of Hanmi Pharmaceutical, one of Korea’s top drugmakers, passed away on the early morning of Aug. 2 at the age of 80 from chronic illness.

2020.8.2

Sanofi seeking to walk away from huge deal with Hanmi

Paris-based Sanofi is seeking an exit from a deal with Hanmi Pharmaceutical involving global marketing rights to efpeglenatide, a diabetes drug. Shares of Kospi-listed Hanmi fell almost 10 percent on the news.

2020.5.14